ARA-290, a non-erythropoietic peptide, represents a significant advancement in neuroprotective therapies, particularly for small fiber neuropathy. Engineered to activate the innate repair receptor (IRR) pathway, it offers tissue protection without stimulating red blood cells. Phase II clinical trials have shown efficacy in improving metabolic control and neuropathic symptoms among diabetic patients and individuals with sarcoidosis. With a promising safety profile and ongoing research into various therapeutic applications, ARA-290 is poised to make a considerable impact in neuropathy treatment.
subcutaneous, intravenous
4-8 mg subcutaneous injection
2-4 hours
Requires refrigerated storage
Innate Repair Receptor (IRR), TRPV1 channels
ARA-290 was engineered as a non-erythropoietic analogue of erythropoietin, specifically designed to retain tissue-protective properties while eliminating red blood cell stimulation . The synthetic peptide was developed to target the innate repair receptor (IRR) pathway, which mediates tissue protection and repair responses .
Innate Repair Receptor (IRR)
TRPV1 channels
Research Use Only (RUO) - ARA-290 Research Monograph: Neuroprotective Peptide Insights is currently available for research purposes only and is not approved by regulatory agencies for human therapeutic use.
This report is generated for educational and informational purposes only. All research content is compiled from credible, peer-reviewed, and verified external scientific sources. This material does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare professional before making any decisions related to your health or treatment.
Explore the clinical applications and protocols of ARA-290, a promising peptide in regenerative medicine. Learn about its mechanisms, benefits, and practical guidelines for use.
April 26, 2026
Discover the neuroprotective potential of ARA-290, a peptide showing promise in treating neurological disorders. This article explores its mechanisms, clinical applications, and the latest research findings.
April 23, 2026
Explore the clinical applications and evidence of ARA-290, a neuroprotective peptide. Delve into its mechanisms, benefits, and latest research findings.
April 23, 2026
Explore the mechanism of ARA-290, a peptide with potential therapeutic benefits. Learn how it interacts at the cellular level, its pathways, and implications for regenerative medicine.
April 19, 2026